Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population

Drug Metabolism and Disposition

Volumn 33, Issue 5, 2005, Pages 630-636

  Hichiya, Hiroyuki ^a   Tanaka Kagawa, Toshiko ^a   Soyama, Akiko ^a   Jinno, Hideto ^a   Koyano, Satoru ^a   Katori, Noriko ^a   Matsushima, Erika ^a   Uchiyama, Shigehisa ^a   Tokunaga, Hiroshi ^a   Kimura, Hideo ^b   Minami, Narihiro ^b,c   Katoh, Masaaki ^c   Sugai, Kenji ^c   Goto, Yu Ichi ^b   Tamura, Tomohide ^d   Yamamoto, Noboru ^d   Ohe, Yuichiro ^d   Kunitoh, Hideo ^d   Nokihara, Hiroshi ^d   Yoshida, Teruhiko ^d   Minami, Hironobu ^e   Saijo, Nagahiro ^e   Ando, Masanori ^f   Ozawa, Shogo ^a   Saito, Yoshiro ^a   Sawada, Jun Ichi ^a   more..

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^f MUSASHINO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; CYTOCHROME P450 2C8; OXYGENASE; PACLITAXEL;

ANIMAL CELL; ARTICLE; CODON; ENZYME ACTIVITY; GENE FUNCTION; GENE SEQUENCE; HUMAN; HYDROXYLATION; JAPAN; NONHUMAN; POPULATION GENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN LOCALIZATION; SINGLE NUCLEOTIDE POLYMORPHISM; WESTERN BLOTTING; WILD TYPE;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BLOTTING, WESTERN; CERCOPITHECUS AETHIOPS; COS CELLS; DNA; HUMANS; JAPAN; KINETICS; PLASMIDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEASOME ENDOPEPTIDASE COMPLEX; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPODOPTERA; VARIATION (GENETICS);

INSECTA; UNIDENTIFIED BACULOVIRUS;

EID: 20944438107     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.105.003830     Document Type: Article

References (32)

1. Bahadur N, Leathart JBS, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, Houdt JV, Hendrickx J, Mannens G, and Bohets H (2002) CYP2C8 polymorphisms in Caucasian and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes. Biochem Pharmacol 64:1579-1589.
2. Bandiera S, Weidlich S, Harth V, Broede P, Ko Y, and Friedberg T (2005) Proteasomal degradation of human CYP1B1: effect of the Asn453Ser polymorphism on the post-translational regulation of CYP1B1 expression. Mol Pharmacol 67:435-443.
3. Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, and Hansen KT (2003) CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol 56:305-314.
4. Correia MA (2003) Hepatic cytochrome P450 degradation: mechanistic diversity of the cellular sanitation brigade. Drug Metab Rev 35:107-143.
5. Cresteil T, Monsarrat B, Dubois J, Sonnier M, Alvinerie P, and Gueritte F (2002) Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. Drug Metab Dispos 30:438-445.
6. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, and Goldstein JA (2001) Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597-607.
7. Ekins S, Maenpaa J, and Wrighton SA (1999) In vitro metabolism: subcellular fractions, in Handbook of Drug Metabolism (Woolf TE ed) pp 363-399, Marcel Dekker, New York.
8. Gonzalez FJ, Kimura S, Tamura S, and Gelboin HV (1991) Expression of mammalian cytochrome P450 using baculovirus. Methods Enzymol 206:93-99.
9. Gotoh O (1992) Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 267:83-90.
10. Hanioka N, Tanaka-Kagawa T, Miyata Y, Matsushima E, Makino Y, Ohno A, Yoda R, Jinno H, and Ando M (2003) Functional characterization of three human cytochrome p450 2El variants with amino acid substitutions. Xenobiotica 33:575-586.
11. Imaoka S, Ogawa H, Kimura S, and Gonzalez FJ (1993) Complete cDNA sequence and cDNA-directed expression of CYP4A11, a fatty acid omega-hydroxylase expressed in human kidney. DNA Cell Biol 12:893-899.
12. Inoue K, Inazawa J, Suzuki Y, Shimada T, Yamazaki H, Guengerich FP, and Abe T (1994) Fluorescence in situ hybridization analysis of chromosomal localization of three human cytochrome P450 2C genes (CYP2C8, 2C9 and 2C10) at 10q24.1. Jpn J Hum Genet 39:337-343.
13. Ishikawa C, Ozaki H, Nakajima T, Ishii T, Kanai S, Anjo S, Shirai K, and Inoue I (2004) A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin. J Hum Genet 49:582-585.
14. Iwasaki M, Lindberg RL, Juvonen RO, and Negishi M (1993) Site-directed mutagenesis of mouse steroid 7 alpha-hydroxylase (cytochrome P-450(7) alpha): role of residue-209 in determining steroid-cytochrome P-450 interaction. Biochem J 291:569-573.
15. Jinno H, Tanaka-Kagawa T, Hanioka N, Saeki M, Ishida S, Nishimura T, Ando M, Saito Y, Ozawa S, and Sawada J (2003a) Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos 31:108-113.
16. Jinno H, Tanaka-Kagawa T, Ohno A, Makino Y, Matsushima E, Hanioka N, and Ando M (2003b) Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab Dispos 31:398-403.
17. Kemper B (2004) Structural basis for the role in protein folding of conserved proline-rich regions in cytochromes P450. Toxicol Appl Pharmacol 199:305-315.
18. Kerdpin O, Elliot DJ, Boye SL, Birkett DJ, Yoovathaworn K, and Miners JO (2004) Differential contribution of active site residues in substrate recognition sites 1 and 5 to cytochrome P450 2C8 substrate selectivity and regioselectivity. Biochemistry 43:7834-7842.
19. Klose TS, Blaisdell JA, and Goldstein JA (1999) Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol 13:289-295.
20. Melet A, Marques-Soares C, Schoch GA, Macherey AC, Jaouen M, Dansette PM, Sari MA, Johnson EF, and Mansuy D (2004) Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry 43: 15379-15392.
21. Mück W (1998) Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Drugs 56 (Suppl 1):15-23.
22. Nadin L and Murray M (1999) Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes. Biochem Pharmacol 58:1201-1208.
23. Nakajima M, Fujiki Y, Noda K, Ohtsuka H, Ohkuni H, Kyo S, Inoue M, Kuroiwa Y, and Yokoi T (2003) Genetic polymorphisms of CYP2C8 in Japanese population. Drug Metab Dispos 31:687-690.
24. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, and Yokoi T (2000) A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos 28:1303-1310.
25. Projean D, Baune B, Farinotti R, Flinois JP, Beaune P, Taburet AM, and Ducharme J (2003) In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos 31:748-754.
26. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, and Harris JW (1994) Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54:5543-5546.
27. Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, and Johnson EF (2004) Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J Biol Chem 279:9497-9503.
28. Schwarz D, Kisselev P, Honeck H, Cascorbi I, Schunck WH, and Roots I (2001) Co-expression of human cytochrome P4501A1 (CYP1A1) variants and human NADPH-cytochrome P450 reductase in the baculovirus/insect cell system. Xenobiotica 31:345-356.
29. Soyama A, Saito Y, Hanioka N, Murayama N, Nakajima O, Katori N, Ishida S, Sai K, Ozawa S, and Sawada J (2001) Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol Pharm Bull 24:1427-1430.
30. Soyama A, Saito Y, Komamura K, Ueno K, Kamakura S, Ozawa S, and Sawada J (2002) Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift. Drug Metab Pharamacokinet 17:373-377.
31. Taniguchi R, Kumai T, Matsumoto N, Watanabe M, Kamio K, Suzuki S, and Kobayashi S (2005) Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4. J Pharmacol Sci 97:83-90.
32. Zeldin DC, Moomaw CR, Jesse N, Tomer KB, Beetham J, Hammock BD, and Wu S (1996) Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. Arch Biochem Biophys 330:87-96.